InMed Pharmaceuticals Inc. - 8-K Filing
InMed Pharmaceuticals amends pre-merger financing agreement with $200M additional investment from existing and new investors, extending Mentari's cash runway to 2029. (Items: 7.01 Regulation FD Disclosure, 8.01 of this Current Report on Form 8-K), 9.01 Financial Statements and Exhibits)
Tickers: $INM